ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO180

Hyperkalemia in CKD: Can Virtual Patient Simulation Improve Management?

Session Information

  • Educational Research
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Educational Research

  • 800 Educational Research

Authors

  • Larkin, Amy, Medscape Education, Nicholasville, Kentucky, United States
  • Gitzinger, Susan, Medscape, Medford, New Jersey, United States
  • Blatherwick, Donald, Medscape, Medford, New Jersey, United States
  • Warters, Martin, Medscape, Medford, New Jersey, United States
  • Littman, Gwen S., WedMD, Durham, North Carolina, United States
Background

We sought to determine if an online, virtual patient simulation (VPS)-based continuing medical education (CME) intervention could improve performance of nephrologists and primary care physicians (PCPs) in the evidence-based management of chronic kidney disease (CKD)-associated hyperkalemia.

Methods

The intervention comprised two patients presenting in a VPS platform that allows learners to order lab tests, make diagnoses, and prescribe treatments mirroring the scope and depth of actual practice. Eevidence-based clinical guidance (CG) was provided following each decision, followed by the opportunity to modify their clinical decisions. Each user’s baseline (pre-CG) decisions were compared to their post-CG decisions using a 2-tailed paired t-test to determine P values. The CME launched online February 13, 2018, and data were collected through May 7, 2018.

Results

Case 1 (n=51 Nephrologists; n=367 PCPs):
Diagnose hyperkalemia: 16% improvement among nephrologists (51% pre-CG vs 67% post-CG; P=.051), 51% improvement among PCPs (50% pre-CG vs 71% post-CG; P<.001)
Continue/modify spironolactone therapy: 12% improvement among nephrologists (14% pre-CG vs 26% post-CG; P=.085), 15% improvement among PCPs (11% pre-CG vs 26% post-CG; P<.001)
Order follow-up potassium test: 12% improvement among nephrologists (59% pre-CG vs 71% post-CG; P=.105), 17% improvement among PCPs (50% pre-CG vs 67% post-CG; P<.001)
Prescribe a potassium binder: 22% improvement among nephrologists (16% pre-CG vs 18% post-CG; P=.395), 0% improvement among PCPs (4% pre-CG vs 4% post-CG; P=.5)

Case 2 (n=34 Nephrologists; n=307 PCPs):
Diagnose CKD Stage 3b: 41% improvement among nephrologists (9% pre-CG vs 50% post-CG; P<.001), 26% improvement among PCPs (17% pre-CG vs 43% post-CG; P<.001)
Appropriately initiate hyperkalemia therapy: 47% improvement among nephrologists (18% pre-CG vs 67% post-CG; P<.001), 48% improvement among PCPs (7% pre-CG vs 54% post-CG; P<.001)
Appropriately discontinue spironolactone: 29% improvement among nephrologists (9% pre-CG vs 38% post-CG; P=.001), 24% improvement among PCPs (30% pre-CG vs 54% post-CG; P<.001)

Conclusion

VPS that immerses and engages physicians in an authentic and practical learning experience improved evidence-based clinical decisions of both nephrologists and PCPs related to hyperkalemia management.